40 results
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Aug 23
Notice of Annual General and Special Meeting of Shareholders
5:15pm
;
Code of Conduct and Ethics
(kk) review and discuss the Company's Code of Business Conduct and Ethics (the "Code") and the actions taken to monitor
20-F/A
2021 FY
REPCF
Replicel Life Sciences Inc.
12 Sep 22
Annual report (foreign) (amended)
6:17pm
is defined in Nasdaq Marketplace Rule 5605(a)(2).
ITEM 16B Code of Ethics
Code of Ethics
Effective July 15, 2004, our board of directors adopted a Code … of Business Conduct and Ethics that applies to, among other persons, our president (being our principal executive officer) and our chief financial
6-K
EX-99
REPCF
Replicel Life Sciences Inc.
26 Jul 22
Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
1:45pm
according to Helsinki guidelines and samples are collected after patient consent and ethics approval under relevant jurisdiction laws.
About
6-K
EX-99.1
p7p5l2htnwyi427p
18 Nov 21
Notice of Annual General and Special Meeting of Shareholders
10:36am
6-K
EX-99.2
x9h s19v3oy58r76uf
16 Nov 21
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
4:03pm
20-F/A
pdgqa43pw nbmd
31 Mar 21
Annual report (foreign) (amended)
12:00am
6-K
EX-99.1
t419c1h3d1d 8y0x
13 Nov 20
Notice of Annual General and Special Meeting of Shareholders
12:00am
6-K
EX-99.1
d734fzmm
6 Nov 19
Notice of Annual General and Special Meeting of Shareholders
12:00am
6-K
EX-99.1
9t33rkqhfkp99l6rm00
22 Jan 19
Current report (foreign)
4:43pm
20-F/A
o50nxubzi
12 Jan 18
Annual report (foreign) (amended)
12:00am
6-K
EX-99.1
phzl 2704puvtx995l
23 Jul 15
RepliCel Receives Two Important Approvals for Dermal Rejuvenation Clinical Trial
12:00am